Panzynorm Forte (Amylase, Lipase, Protease)

The three enzymes act in the gastrointestinal tract: amylase breaks down carbohydrates, lipase hydrolyzes dietary fats, and protease digests proteins. By providing these enzymes externally, the product compensates for the reduced endogenous pancreatic output, facilitating normal macronutrient breakdown and absorption.

The specific dose of Panzynorm Forte is individualized. A qualified prescriber determines the appropriate amount based on the patient’s degree of pancreatic insufficiency, dietary intake, and clinical response. Patients should follow the prescribing healthcare professional’s instructions.

Safety data for Panzynorm Forte in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To request Panzynorm Forte, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Panzynorm Forte combines three key enzymes—amylase, lipase, and protease—in a single oral formulation, similar to other pancreatic enzyme replacement therapies. Compared with products that contain only lipase, Panzynorm offers broader macronutrient coverage, which may be advantageous for patients with mixed digestive deficiencies.

Panzynorm Forte should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain enzyme stability and potency.

Panzynorm Forte is taken orally, usually with meals or snacks to coincide with food intake. The capsule should be swallowed whole with water unless the prescriber advises otherwise. Proper timing with meals maximizes enzyme activity in the digestive tract.

The most serious risks include allergic reactions such as rash, urticaria, or anaphylaxis, and severe abdominal pain that may signal an underlying complication. Patients experiencing any signs of hypersensitivity or intense gastrointestinal distress should seek immediate medical attention.

Individuals with known hypersensitivity to any of the enzyme components (amylase, lipase, protease) or to other ingredients in the formulation should avoid Panzynorm Forte. It is also contraindicated in patients who have experienced severe allergic reactions to similar pancreatic enzyme products.